Skip navigation

Bridging the Gap

Sponsored Renasight™ genetic testing for eligible* Black patients with non-diabetic chronic kidney disease†

African Americans are 3 to 4 times more likely to develop kidney failure, which has raised the possibility of a genetic cause for this disparity.1, 2 Research has discovered hundreds of genes linked to increased risk for kidney disease, including the APOL1 gene – thought to be associated with a rapidly progressive form of chronic kidney disease for people of African ancestry who have high risk variants. Genetic testing is the first step for patients to understand their genetic risk and better inform their treatment options.

Vertex Pharmaceuticals is sponsoring a no-cost testing program to provide Renasight™ genetic test to eligible* individuals who have been diagnosed with non-diabetic chronic kidney disease.

Program Overview

Natera and Vertex Pharmaceuticals are working together to raise awareness about the genetic causes of kidney disease in the Black community and to reduce the barriers associated with genetic testing. Vertex Pharmaceuticals is sponsoring a no-cost testing program with Natera to provide the Renasight™ genetic test and genetic counseling to eligible* individuals. Through this program more patients will have access to genetic testing which may help to provide answers explaining the increased risk of kidney disease and provide clarity for improved disease management decisions.

*Sponsored Renasight™ Genetic Testing Program Eligibility

Patients who meet all of the following criteria are eligible for the Renasight™ sponsored testing program:

Patients of African ancestry including those who self-identify as Black, African American, African, or Afro-Caribbean

Patient has been diagnosed with non-diabetic chronic kidney disease (CKD) or end stage renal disease (ESRD)

Patient is not receiving dialysis treatment and has not received a kidney transplant

Commitment to Privacy

Your Information. Your Rights. Our Responsibilities.

  • Eligible patients and healthcare providers have no expectations or obligations to Natera or Vertex Pharmaceuticals to participate in the sponsored Renasight™ Genetic Testing Program.
  • All tests must be ordered by a qualified healthcare provider based on clinical necessity for the patient. Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™
    Genetic Testing Program and complete a signed attestation form for each patient.
  • Natera never distributes identifiable patient data or information. Natera will never share identifiable patient data or information. Vertex Pharmaceuticals and third parties may receive aggregated, de-identified data, and contact information for healthcare providers that participate in this sponsored Renasight™ genetic testing program.
  • Click here to learn more about how your medical information is used and protected; and, how you can get access to this information.

Learn more about the sponsored Renasight™ genetic testing program

Select your user type to proceed!

† The Sponsored Renasight™ Genetic Testing Program is funded by Vertex Pharmaceuticals


1Umeukeje EM, Young BA. Genetics and ESKD Disparities in African Americans. Am J Kidney Dis. 2019 Dec;74(6):811-821. doi: 10.1053/j.ajkd.2019.06.006. Epub 2019 Oct 10. PMID: 31606237; PMCID: PMC7373097.


icon-angle icon-bars icon-times